US Companion Diagnostic Markets, Q4 2021 Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostic Markets 2021-2025" report has been added to ResearchAndMarkets.com's offering.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.

Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities.

And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

Market Trends

Factors Driving Growth

• Level of Care
• Immuno-oncology
• Liability
• Aging Population

Factors Limiting Growth

• State of knowledge
• Genetic Blizzard
• Protocol Resistance
• Regulation and coverage

Instrumentation and Automation

• Instruments Key to Market Share
• Bioinformatics Plays a Role

Diagnostic Technology Development

• Next Generation Sequencing Fuels a Revolution
• Single Cell Genomics Changes the Picture
• Pharmacogenomics Blurs Diagnosis and Treatment
• CGES Testing, A Brave New World
• Biochips/Giant magneto resistance based assay

Companion Diagnostics Recent Developments

• HTG Molecular Diagnostics 2020 Revenues Fall 56%
• Oncocyte Details Expansions Plans
• Agilent Acquires Resolution Biosciences
• Qiagen, Inovio Expand CDx Partnership
• AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
• NeoGenomics to Grow Through CDx Agreements, Acquisitions
• Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
• Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
• FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
• Promega to Develop MSI Assay as CDx
• HTG Molecular Q2 Revenues Drop 66 Percent
• Guardant Health to Develop CDx for Janssen
• Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx .
• FDA Approval for FoundationOneCDx
• FDA finalizes CDx Guidance
• QIAGEN Launches CDx Therascreen BRAF Test
• Myriad Genetics Seeks Approval for Companion Diagnostic
• ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
• QIAGEN Builds on Global Collaboration with Amgen
• Foundation Medicine nabs 19th companion Dx
• Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
• Myriad Wins Japanese Approval for BRACAnalysis
• Fujitsu Improves Efficiency in Cancer Genomic Medicine
• Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
• Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
• Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
• Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
• Universal Genetic Testing for All Breast Cancer Patients
• Exact Sciences buys Genomic Health
• Biodesix Highlights Pipeline and Companion Diagnostic Development

For more information about this report visit https://www.researchandmarkets.com/r/bjgro2

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900